Markets head into the final session of June with a hawkish Federal Reserve in the background. Chair Kevin Warsh's June 17 FOMC meeting left rates at 3.50%–3.75% and removed the easing bias, and CME FedWatch shows roughly an 80% probability of zero cuts for all of 2026. The May PCE release on June 26 adds a fresh data point. Against that backdrop, the back half of the week brought a clear sector-rotation pattern in sell-side research, with consumer, healthcare, industrial, and rail names drawing fresh upgrades rather than megacap technology. The five stocks below head into Monday with improving setups.
Crocs (CROX) — Piper Sandler doubles its price target
Crocs is the casual footwear company behind the Crocs and HEYDUDE brands. On June 26, Piper Sandler analyst Anna Andreeva upgraded the stock from Neutral to Overweight and raised her price target from $95 to $150, one of the more dramatic single-day moves of the week. She joins Baird at Outperform with $150, Bank of America at Buy with $145, and Needham at Buy with $132. Goldman Sachs sits on the other side at Sell with an $81 target, making CROX one of the more contested consumer names.
Shares closed at $127.76 on June 26, up 7.47%, with a market cap of $6.35 billion and a trailing P/E of 10.28. The 52-week range is $73.21 to $129.79, putting the stock at the upper end. Consensus is Buy, with 4 of 8 analysts bullish, an average target of $125, a median of $128.50, a high of $150, and a low of $81. The dispersion is the story: bulls underwrite brand momentum and margin recovery, while bears focus on HEYDUDE execution and discretionary softness.
Risks: HEYDUDE brand turnaround remains unproven, U.S. discretionary spending could weaken if the labor market cools, retail footwear inventories remain elevated, and the bull-bear target gap implies elevated single-stock volatility.
Icon plc (ICLR) — RBC flips from skeptic to bull
Icon is a leading clinical research organization that runs late-stage drug trials for biopharma sponsors. On June 25, RBC Capital Markets analyst Ryan Halsted upgraded the stock from Sector Perform to Outperform and raised his price target from $126 to $185, citing first-quarter 2026 results that confirmed the strong fourth quarter of 2025 was sustainable. The upgrade carries weight because RBC had been one of the more cautious voices on the CRO group. Mizuho's Ann Hynes followed on June 26 with Outperform at $190, and TD Cowen, BMO, and Evercore all sit at Buy or Outperform with targets between $180 and $197. JP Morgan at Neutral and Bank of America at Underperform represent the bear case.
Shares closed at $169.86 on June 26, up 5.53%, with a market cap of $13.0 billion and a trailing P/E of 13.85. The 52-week range is $66.57 to $211. Consensus is Buy, with 6 of 11 analysts bullish, an average target of $175.36, a median of $180, a high of $197, and a low of $150. The setup combines a recovering bookings backdrop with a valuation still well below the 52-week high.
Risks: Biotech funding remains uneven and could pressure CRO bookings, large pharma decision timelines on trial awards have lengthened, foreign exchange exposure is meaningful given the global footprint, and cancellation activity above plan would directly hit revenue conversion.
Keurig Dr Pepper (KDP) — Barclays leans into the planned separation
Keurig Dr Pepper makes coffee systems and a broad portfolio of beverages including Dr Pepper, Snapple, and Canada Dry. On June 25, Barclays analyst Lauren Lieberman upgraded the stock from Equal-Weight to Overweight and raised her price target from $30 to $36, citing improved leverage and decreasing transaction uncertainty ahead of the planned separation of the coffee and beverage businesses. That thesis aligns with Wells Fargo at Overweight with $37, UBS at Buy with $34, JP Morgan at Overweight with $33, and Piper Sandler at Overweight with $38.
Shares closed at $33.40 on June 26, up 2.71%, with a market cap of $45.4 billion, a trailing P/E of 16.53, and a dividend yield near 3%. The 52-week range is $24.88 to $35.94. Consensus is Buy, with 6 of 9 analysts bullish, an average target of $33.33, a median of $33, a high of $38, and a low of $28. The setup is a defensive, dividend-paying staples name where a clearly defined corporate action is collapsing the deal-complexity discount.
Risks: The separation timeline could slip, coffee volumes remain pressured by at-home normalization, private-label competition in cold beverages is intensifying, and debt or tax surprises tied to the split could change the leverage math.
Canadian National Railway (CNI) — Evercore sees a beat-and-raise setup
Canadian National Railway operates one of the largest rail networks in North America, spanning Canada and the U.S. Midwest and Gulf Coast. On June 25, Evercore ISI analyst Jonathan Chappell upgraded the stock from In-Line to Outperform and raised his price target from $108 to $124, arguing CNI is positioned for a significant beat and raise at second-quarter earnings for the first time in nearly three years. CIBC at Outperformer with $185, Bank of America at Buy with $134, and RBC at Outperform with $178 round out a constructive rail panel.
Shares closed at $120.56 on June 26, up 0.17%, with a market cap of $73.1 billion, a trailing P/E of 22, and a dividend yield near 2%. The 52-week range is $90.74 to $122.48. Consensus is Buy, with 4 of 8 analysts bullish, an average target of $133.92, a median of $124, a high of $185, and a low of $100. The wide spread reflects different views on intermodal recovery and Canadian grain volumes.
Risks: A weaker industrial backdrop would pressure carload volumes, fuel surcharge timing introduces quarterly noise, Canadian regulatory and labor risk remains an overhang, and currency translation can swing results.
Diageo (DEO) — TD Cowen calls the cyclical bottom in spirits
Diageo is the global spirits company behind Johnnie Walker, Crown Royal, Don Julio, and Guinness. On June 26, TD Cowen upgraded the stock from Hold to Buy and raised the price target from $88 to $93 as part of a broader sector call arguing that cyclical weakness in alcohol consumption is closer to its end than beginning. Bank of America's Andrea Pistacchi has carried a Buy rating with a $109 target since September 2025.
Shares closed at $83.51 on June 26, up 1.09%, with a market cap of $46.4 billion, a trailing P/E of 18.32, and a dividend yield near 4%. The 52-week range is $72.45 to $116.41. The recent analyst dataset on the ADR is limited, with two current ratings averaging $101 and a high of $109, so consensus should be read with that smaller sample in mind. Editorially, this is a contrarian setup: a defensive staple trading well off its highs with a 4% yield while investors wait for spirits volumes to inflect.
Risks: Premium spirits demand in the U.S. and China has been weaker than management guided, GLP-1 medications continue to be debated as a structural headwind for alcohol consumption, foreign exchange volatility affects reported results, and the limited sell-side dataset means consensus can shift quickly when more analysts refresh models.
Found this helpful? Share it with others.